Clinical trials: Osteoporosis, Post-Menopausal
Osteoporosis in Post-menopausal Women
Bone Health in Postmenopausal Women: The Effect of Exercise With or Without Medication for Osteoporosis
Osteoporosis is a systemic bone disorder characterised by a reduced bone mass and structural deterioration, increasing the risk of fragility fractures, particularly in women post-menopause.
- Trial name
- BEAT-OP (NCT07267325)
- Testing
- EXERCISE TRAINING, Antiresorptive medication (routine clinical care)
- Where
- United Kingdom
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Loughborough University
Osteoporosis in Post-menopausal Women
Safety and Efficacy of Whole-body Vibration as add-on Treatment of Osteoporosis in Post-menopausal Women
Multicentered, randomized study of safety and efficacy of whole-body vibration (WBV) as add on to standard pharmacological treatment of osteoporosis (alendronate 70 mg/ week or raloxifene 60 mg/day) in post-menopausal women.
- Trial name
- NCT01415050
- Testing
- Whole body vibration
- Where
- 5 sites in Germany
- Volunteers
- 80 people
- Sponsor
- X-pert Med GmbH
Post Menopausal Osteoporosis
ExBonAdAsia Study: A Study of Once Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.
This single arm study will continue drug safety surveillance, and assessment of adherence, in patients with postmenopausal osteoporosis who have received monthly oral Bonviva in ML19930, the BonAdAsia study.
- Trial name
- NCT00545090
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 17 sites in Hong Kong, Indonesia and 3 more
- Volunteers
- 561 people
- Sponsor
- Hoffmann-La Roche
Osteoporosis, Bone Loss, Postmenopausal
DPP4-Inhibitors and Bone Metabolism in Diabetes
Background Bone frailty and fractures are common conditions in patients with type 2 diabetes (T2D) and represent a major cause of morbidity and hospitalization in this population.
- Conditions
- Osteoporosis, Bone Loss, Postmenopausal, Diabetes Mellitus Type 2
- Trial name
- SlowDOWN (NCT06770894)
- Testing
- Sitagliptin 100 mg
- Where
- Italy
- Volunteers
- 132 people
- Sponsor
- Azienda Policlinico Umberto I
Osteopenia, Osteoporosis
Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis
The primary objective was to describe the safety and tolerability of up to 10 years or 7 years denosumab administration as measured by adverse event monitoring, immunogenicity and safety laboratory parameters in participants who…
- Trial name
- NCT00523341
- Testing
- Denosumab
- Volunteers
- 4,550 people
- Sponsor
- Amgen
Osteoporosis, Postmenopausal
Peri-implant Bone Changes in Post-menopausal Osteoporotic Women
This is a prospective case series study aiming to evaluate the effect of post-menopausal osteoporosis on the jaw bone around dental implants with a modified titanium surface.
- Trial name
- NCT02884401
- Testing
- Dental implant placement (Straumann® Bone Level Tapered, BLT, Roxolid® SLActive®)
- Where
- United Kingdom
- Volunteers
- 27 people
- Sponsor
- Queen Mary University of London
Postmenopausal Osteoporosis
Pravastatin Reduces Acute Phase Response of Zoledronic Acid
Acute phase response (APR) is one of the most common adverse events in osteoporosis with zoledronic acid treatment. It's reported that this reaction is related to the blockade of the mevalonate pathway, leading to isopentenyl…
- Trial name
- NCT04719481
- Testing
- Pravastatin Sodium 80 MG
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Peking University Third Hospital
Low Bone Mass, Low Bone Mineral Density
A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab
To characterize the effects of discontinuation of denosumab therapy on variables of bone histology in postmenopausal women with low bone mass or osteoporosis.
- Conditions
- Low Bone Mass, Low Bone Mineral Density, Osteoporosis, Postmenopausal Osteoporosis
- Trial name
- NCT00887965
- Testing
- Previous denosumab
- Volunteers
- 15 people
- Sponsor
- Amgen
Menopausal Osteoporosis
Effect of VSL#3 on Bone Mineral Density in Postmenopausal Women
Osteoporosis has a devastating impact on quality of life of postmenopausal women, and is a significant cause of disability and morbidity.
- Trial name
- ProBoneVSL (NCT03165747)
- Testing
- VSL#3
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Emory University
Osteoporosis, Postmenopausal, Osteoporosis
Preventing Osteoporosis Using Denosumab
The purpose of this research study is to find out if denosumab (Prolia®), an injection given in the arm under the skin every 6 months, works to treat bone loss and prevent it from worsening in older men and women (ages 65 and…
- Conditions
- Osteoporosis, Postmenopausal, Osteoporosis, Osteoporotic Fractures
- Trial name
- PROUD (NCT02753283)
- Testing
- denosumab, Calcium and Vitamin D
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Susan L. Greenspan
Osteoporosis
TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
This is an 18-month, double-blind, placebo-controlled, Phase III trial with a 12-month interim analysis of the effect of ALX1-11, recombinant human parathyroid hormone (1-84) (rhPTH [1-84]), on fracture incidence in women with…
- Trial name
- NCT00172081
- Testing
- ALX1-11
- Where
- 174 sites in United States, Argentina and 7 more
- Volunteers
- 2,532 people
- Sponsor
- Shire
Osteoporosis
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A double-blind, placebo-controlled, parallel-group study to assess the safety and efficacy of 3 doses of ALX1-11 (recombinant human parathyroid hormone [rhPTH(1-84)])(50, 75 and 100 µg) in the treatment of postmenopausal…
- Trial name
- NCT00172107
- Testing
- ALX1-11 50 mcg, ALX1-11 75mcg, ALX1-11
- Where
- 19 sites in United States, Canada
- Volunteers
- 217 people
- Sponsor
- Shire
Osteoporosis, Postmenopausal
Switching From Oral Bisphosphonates to Bazedoxifene to Evaluate Effects on Bone Mineral Density in Postmenopausal Women
The aim of this study is see the changes in bone mineral density after discontinuation or stop the use of bisphosphonates and make the switch to bazedoxifene).
- Trial name
- NCT02090400
- Testing
- Bazedoxifene, Calcium/Vit D
- Where
- 3 sites in Spain
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Instituto Palacios
Primary Hyperparathyroidism, Osteoporosis, Postmenopausal
Circulating miRNA in Primary Hyperparathyroidism
The goal of this study is to: 1. Analyze the expression levels of circulating (serum) miRNAs in primary hyperparathyroidism patients with and without osteoporosis, and patients with osteoporosis undergoing thyroidectomy, and to…
- Trial name
- NCT03931109
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- University of Pennsylvania
Postmenopausal Osteoporosis
A Study to Evaluate the Efficacy and Safety of LY06006 in Postmenopausal Women With Osteoporosis at High Risk for Fracture
A multicenter, randomized, double-blind, placebo-controlled phase III clinical study will be conducted to evaluate the efficacy and safety of LY06006 in the treatment of postmenopausal women with osteoporosis at high risk for…
- Trial name
- NCT05060406
- Testing
- LY06006
- Where
- China
- Volunteers
- 448 people
- Sponsor
- Luye Pharma Group Ltd.
Postmenopausal Osteoporosis
BEATRIS Study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis
This 2 arm study will assess the impact of Bone Marker Feedback (BMF), using blood sampling and communication of the results at 2 months, on adherence to monthly Bonviva (150mg po) in women with post-menopausal osteoporosis.
- Trial name
- NCT00545909
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 57 sites in Austria, Belgium and 3 more
- Volunteers
- 585 people
- Sponsor
- Hoffmann-La Roche
Postmenopausal Osteoporosis
Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis
This study will determine whether treatment with AMG 162 can prevent lumbar spine bone loss in both early and late postmenopausal women with osteopenia, and to further test the safety and tolerability of AMG 162 in this…
- Trial name
- NCT00091793
- Testing
- AMG 162
- Volunteers
- 332 people
- Sponsor
- Amgen
Post-Menopausal Osteoporosis
A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis
To evaluate the noninferiority of a 6-month treatment with 210 mg romosozumab at 90 mg/mL administered subcutaneously (SC) once a month (QM) in postmenopausal women with osteoporosis either by healthcare provider (HCP)…
- Trial name
- NCT03432533
- Testing
- romosozumab HCP administration with PFS, romosozumab self-administration with AI/Pen
- Where
- 46 sites in United States, Poland and 1 more
- Volunteers
- 283 people
- Sponsor
- Amgen
Postmenopausal Osteoporosis
A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia
This study will investigate participant satisfaction (including compliance, preference, tolerability) with once-monthly Bonviva in women with post-menopausal osteoporosis or osteopenia transitioned from once-weekly alendronate or…
- Trial name
- NCT02604836
- Testing
- Ibandronate
- Where
- 142 sites in United States
- Volunteers
- 1,711 people
- Sponsor
- Hoffmann-La Roche
Hearing Loss, Osteoporosis, Postmenopausal
Hearing Loss and Osteoporosis
To compare the audiological profiles in postmenopausal women with and without osteoporosis and to examine the pattern of hearing loss in osteoporotic patients.
- Trial name
- NCT03895333
- Testing
- Audiological profiling and bone mineral densitometry measurement
- Where
- Turkey (Türkiye)
- Volunteers
- 160 people
- Sponsor
- Kanuni Sultan Suleyman Training and Research Hospital